What does deepull do?
Deepull develops culture-free diagnostic solutions for sepsis and acute infections, including its UllCORE BSI Test that uses multiplex PCR to rapidly detect a wide range of pathogens and antibiotic resistance genes directly from whole blood.
How much did they raise?
The company raised €50M in a Series C round led by Columbus Venture Partners, Panakès Partners, and Mérieux Equity Partners, with participation from existing investors such as Asabys Partners, Innvierte-CDTI, We Venture Capital, UI Investissement, Axis-ICO, Aliath Bioventures, and Kurma Partners.
What are their plans for the money?
With the new funding, Deepull plans to finalize clinical validation and expedite the regulatory approval process for its UllCORE diagnostic system, aiming to reduce diagnosis time for sepsis and improve patient treatment outcomes.
What have they achieved so far?
Deepull has already made significant progress with its UllCORE diagnostic system, which targets 95% of sepsis-causing pathogens and provides critical test results in about one hour, marking a major advancement in rapid, culture-free diagnostics.
